Scholarlink

Background <p>This study aimed to investigate the diagnostic value of [gallium-68]-labeled fibroblast activation protein inhibitor ([<sup>68</sup>Ga]Ga-FAPI-04) versus [fluorine-18]-fluorodeoxyglucose positron emission tomography/computed tomography ([<sup>18</sup>F]-FDG PET/CT), contrast-enhanced computed tomography (CECT), and magnetic resonance imaging (MRI) in detecting peritoneal carcinomatosis (PC).</p> Methods <p>The study enrolled patients with suspected peritoneal malignancy. [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT was compared with three alternative modalities in terms of diagnostic efficacy and quantitative metrics. Diagnostic performance was assessed across morphologic subtypes in confirmed PC.</p> Results <p>In this study, 261 patients underwent [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]-FDG PET/CT, 155 completed CECT, and 43 completed MRI. Patient-based detection accuracy for PC improved from 65.2 % (101/155) for CECT, 83.7 % (36/43) for MRI, and 87.7 % (229/261) for [<sup>18</sup>F]-FDG PET/CT to 95.8 % (250/261) for [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT. The region-based diagnostic accuracy improved from 47.8 % (97/203) for CECT, 73.1 % (49/67) for MRI, and 61.1 % (124/203) for [<sup>18</sup>F]-FDG PET/CT to 92.6 % (188/203) for [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT. Compared with [<sup>18</sup>F]-FDG PET/CT, CECT and MRI, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT detected more involved peritoneal metastatic regions and thus produced a higher peritoneal cancer index (PCI) score (median PCI, 8 vs 5 vs 2 vs 4). For semiquantitative evaluation, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT exhibited a significantly higher maximum standardized uptake value (SUVmax) (5.1 ± 2.6 vs 4.2 ± 3.0), SUVmean (3.1 ± 1.4 vs 2.5 ± 1.4), and tumor-to-background ratio (TBR) (7.8 ± 4.8 vs 2.6 ± 1.9) for PC than [<sup>18</sup>F]-FDG (<i>P</i> &lt; 0.001). Across all five morphologic subtypes of PC, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT maintained superior diagnostic performance over both [<sup>18</sup>F]-FDG PET/CT and CECT.</p> Conclusions <p>[<sup>68</sup>Ga]Ga-FAPI-04 PET/CT outperformed CECT, MRI, and [<sup>18</sup>F]-FDG PET/CT for PC detection, with consistent performance across all morphologic subtypes. Its superiority may improve clinical decision-making, rendering it the preferred modality for inconclusive alternative imaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Superiority of [68Ga]Ga-FAPI-04 Over [18F]-FDG PET/CT and Conventional Imaging in Detecting Peritoneal Carcinomatosis

  • 期刊论文

  • 发表日期：

    2026年5月11日

查看全文
  • Xiaolin Chen,
  • Mengjiao Wang,
  • Yan Zhao,
  • Xiao Pang,
  • Ruoxi Yang,
  • Fenglian Jing,
  • Yunuan Liu,
  • Meng Dai,
  • Yuhan Sun,
  • Qiang Fu,
  • Xiaoshan Chen,
  • Xinming Zhao

摘要

Background

This study aimed to investigate the diagnostic value of [gallium-68]-labeled fibroblast activation protein inhibitor ([68Ga]Ga-FAPI-04) versus [fluorine-18]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT), contrast-enhanced computed tomography (CECT), and magnetic resonance imaging (MRI) in detecting peritoneal carcinomatosis (PC).

Methods

The study enrolled patients with suspected peritoneal malignancy. [68Ga]Ga-FAPI-04 PET/CT was compared with three alternative modalities in terms of diagnostic efficacy and quantitative metrics. Diagnostic performance was assessed across morphologic subtypes in confirmed PC.

Results

In this study, 261 patients underwent [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT, 155 completed CECT, and 43 completed MRI. Patient-based detection accuracy for PC improved from 65.2 % (101/155) for CECT, 83.7 % (36/43) for MRI, and 87.7 % (229/261) for [18F]-FDG PET/CT to 95.8 % (250/261) for [68Ga]Ga-FAPI-04 PET/CT. The region-based diagnostic accuracy improved from 47.8 % (97/203) for CECT, 73.1 % (49/67) for MRI, and 61.1 % (124/203) for [18F]-FDG PET/CT to 92.6 % (188/203) for [68Ga]Ga-FAPI-04 PET/CT. Compared with [18F]-FDG PET/CT, CECT and MRI, [68Ga]Ga-FAPI-04 PET/CT detected more involved peritoneal metastatic regions and thus produced a higher peritoneal cancer index (PCI) score (median PCI, 8 vs 5 vs 2 vs 4). For semiquantitative evaluation, [68Ga]Ga-FAPI-04 PET/CT exhibited a significantly higher maximum standardized uptake value (SUVmax) (5.1 ± 2.6 vs 4.2 ± 3.0), SUVmean (3.1 ± 1.4 vs 2.5 ± 1.4), and tumor-to-background ratio (TBR) (7.8 ± 4.8 vs 2.6 ± 1.9) for PC than [18F]-FDG (P < 0.001). Across all five morphologic subtypes of PC, [68Ga]Ga-FAPI-04 PET/CT maintained superior diagnostic performance over both [18F]-FDG PET/CT and CECT.

Conclusions

[68Ga]Ga-FAPI-04 PET/CT outperformed CECT, MRI, and [18F]-FDG PET/CT for PC detection, with consistent performance across all morphologic subtypes. Its superiority may improve clinical decision-making, rendering it the preferred modality for inconclusive alternative imaging.